Internet Resources for Your Patients

Internet Resources for Your Patients

There are many useful resources available online that may help your patients understand and manage their treatment with TREMFYA™ and their disease. You may find the Web sites listed here helpful as referrals in educating your patients about their condition.

TREMFYA™ Patient Web Site

TremfyaInfo.com

This Web site contains information about TREMFYA™.

Janssen Biotech, Inc., the maker of TREMFYA™, does not endorse and is not responsible for the content of any of the Web sites listed below, or the services provided by these organizations. Clicking on any of the links below will take you to a Web site to which our privacy policy does not apply. We encourage you to read the privacy policy of every Web site you visit.

Advocacy Connector

Advocacy Connector

This Web site provides links to a range of national and state-specific resources for dermatology. These resources include sites for clinical trials, financial support, legal assistance, and research. Links are provided for those seeking resources in areas such as pain management, caregiver support, and counseling, among a host of others. This list is updated regularly and is not comprehensive, so please check the site for specific content.

American Academy of Dermatology

AAD.org

The American Academy of Dermatology is dedicated to providing dermatologists with the information and resources they need to serve their patients. Additionally, patients can get expert insights into the care and treatment of their skin, hair, and nails for a lifetime of healthy habits.

National Psoriasis Foundation

Psoriasis.org

The National Psoriasis Foundation (NPF) is a non-profit organization with a mission to drive efforts to cure psoriatic disease and improve the lives of those affected.

Indication

TREMFYA™ is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA™ is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. TREMFYA™ is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA™ after physician approval and proper training.

Important Safety Information For TREMFYA

Important Safety Information

Infections
TREMFYA™ may increase the risk of infection. Treatment with TREMFYA™ should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA™ in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA™ to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA™ until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA™. Initiate treatment of latent TB prior to administering TREMFYA™. Monitor patients for signs and symptoms of active TB during and after TREMFYA™ treatment. Do not administer TREMFYA™ to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA™, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA™.

Adverse Reactions
Most common (≥1%) adverse reactions associated with TREMFYA™ include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA™.  Provide the Medication Guide to your patients and encourage discussion.

067010-170208